請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73989
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 胡忠怡 | |
dc.contributor.author | Yi-Chen Chen | en |
dc.contributor.author | 陳怡臻 | zh_TW |
dc.date.accessioned | 2021-06-17T08:15:58Z | - |
dc.date.available | 2019-08-27 | |
dc.date.copyright | 2019-08-27 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-08-14 | |
dc.identifier.citation | 1 Paul S, Kantarjian H & Jabbour EJ. Adult Acute Lymphoblastic Leukemia. Mayo Clinic Proceedings 91, 1645-1666, (2016).
2 Terwilliger T & Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer Journal 7, e577, (2017). 3 Pui C-H, Relling MV & Downing JR. Acute Lymphoblastic Leukemia. New England Journal of Medicine 350, 1535-1548, (2004). 4 衛生福利部國民健康署. 中華民國 105 年 癌症登記報告, <https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=10227> (2018). 5 Inaba H, Greaves M & Mullighan CG. Acute lymphoblastic leukaemia. The Lancet 381, 1943-1955, (2013). 6 蕭志誠. 兒童急性白血病, <https://www1.cgmh.org.tw/lhcc/02.info/02.1.2.TxInfo/Tx_07.children10.pdf> ( 7 Sehgal S, Mujtaba S, Gupta D, Aggarwal R & Marwaha R. High incidence of Epstein Barr virus infection in childhood acute lymphocytic lukemia: A preliminary study. Indian Journal of Pathology and Microbiology 53, 63-67, (2010). 8 Geriniere L, Bastion Y, Dumontet C, Salles G, Espinouse D & Coiffier B. Heterogeneity of acute lymphoblastic leukemia in HIV-seropositive patients. Annals of Oncology 5, 437-440, (1994). 9 Chessells JM, Harrison G, Richards SM, Bailey CC, Hill FG, Gibson BE & Hann IM. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Archives of Disease in Childhood 85, 321-325, (2001). 10 長庚紀念醫院. 認識成人急性白血病, <https://www1.cgmh.org.tw/lhcc/02.info/02.1.2.TxInfo/Tx_04.lymphoma01.pdf> ( 11 Hoffbrand AV & Moss PAH. in Chapter 17 Acute lymphoblastic leukemia (Wiley, 2015). 12 中華民國兒童癌症基金會. 兒童白血病衛教手冊, <http://www.ccfroc.org.tw/content_sub.php?id=138&level1ID=12&level2ID=1&level3ID=1> ( 13 Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR & Sultan C. Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group. British Journal of Haematology 33, 451-458, (1976). 14 Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M & Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391-2405, (2016). 15 Pui C-H & Evans WE. Treatment of Acute Lymphoblastic Leukemia. New England Journal of Medicine 354, 166-178, (2006). 16 Liang DC, Yang CP, Lin DT, Hung IJ, Lin KH, Chen JS, Hsiao CC, Chang TT, Peng CT, Lin MT, Chang TK, Jaing TH, Liu HC, Wang LY, Yeh TC, Jou ST, Lu MY, Cheng CN, Sheen JM, Chiou SS, Wu KH, Hung GY, Chen RL, Chen SH, Cheng SN, Chang YH, Chen BW, Ho WL, Wang JL, Lin ST, Hsieh YL, Wang SC, Chang HH, Yang YL, Huang FL, Chang CY, Chang WH & Lin KS. Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia 24, 397-405, (2010). 17 van Dongen JJ, van der Velden VH, Bruggemann M & Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood 125, 3996-4009, (2015). 18 Pui CH & Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov 6, 149-165, (2007). 19 De Braekeleer E, Douet-Guilbert N, Morel F, Le Bris MJ, Basinko A & De Braekeleer M. ETV6 fusion genes in hematological malignancies: a review. Leukemia Research 36, 945-961, (2012). 20 Juarez-Velazquez MR, Salas-Labadia C, Reyes-Leon A, Navarrete-Meneses MP, Fuentes-Panana EM & Perez-Ver P. in Clinical Epidemiology of Acute Lymphoblastic Leukemia - From the Molecules to the Clinic Ch. Chapter 9, (2013). 21 Wang LC, Swat W, Fujiwara Y, Davidson L, Visvader J, Kuo F, Alt FW, Gilliland DG, Golub TR & Orkin SH. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes and Development 12, 2392-2402, (1998). 22 Okuda T, van Deursen J, Hiebert SW, Grosveld G & Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84, 321-330, (1996). 23 Malouf C & Ottersbach K. Molecular processes involved in B cell acute lymphoblastic leukaemia. Cellular and Molecular Life Sciences 75, 417-446, (2018). 24 Shah S, Schrader KA, Waanders E, Timms AE, Vijai J, Miething C, Wechsler J, Yang J, Hayes J, Klein RJ, Zhang J, Wei L, Wu G, Rusch M, Nagahawatte P, Ma J, Chen S-C, Song G, Cheng J, Meyers P, Bhojwani D, Jhanwar S, Maslak P, Fleisher M, Littman J, Offit L, Rau-Murthy R, Fleischut MH, Corines M, Murali R, Gao X, Manschreck C, Kitzing T, Murty VV, Raimondi SC, Kuiper RP, Simons A, Schiffman JD, Onel K, Plon SE, Wheeler DA, Ritter D, Ziegler DS, Tucker K, Sutton R, Chenevix-Trench G, Li J, Huntsman DG, Hansford S, Senz J, Walsh T, Lee M, Hahn CN, Roberts KG, King M-C, Lo SM, Levine RL, Viale A, Socci ND, Nathanson KL, Scott HS, Daly M, Lipkin SM, Lowe SW, Downing JR, Altshuler D, Sandlund JT, Horwitz MS, Mullighan CG & Offit K. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nature Genetics 45, 1226, (2013). 25 Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds SB, Su X, Pui C-H, Relling MV, Evans WE, Shurtleff SA & Downing JR. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758, (2007). 26 Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, Harvey RC, Chen I-M, Clifford RJ, Carroll WL, Reaman G, Bowman WP, Devidas M, Gerhard DS, Yang W, Relling MV, Shurtleff SA, Campana D, Borowitz MJ, Pui C-H, Smith M, Hunger SP, Willman CL & Downing JR. Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia. New England Journal of Medicine 360, 470-480, (2009). 27 Rubnitz JE, Downing JR, Pui CH, Shurtleff SA, Raimondi SC, Evans WE, Head DR, Crist WM, Rivera GK, Hancock ML, Boyett JM, Buijs A, Grosveld G & Behm FG. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. Journal of Clinical Oncology 15, 1150-1157, (1997). 28 Loh ML, Goldwasser MA, Silverman LB, Poon W-M, Vattikuti S, Cardoso A, Neuberg DS, Shannon KM, Sallan SE & Gilliland DG. Prospective analysis of <em>TEL/AML1</em>-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood 107, 4508-4513, (2006). 29 Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, McMillan AK, Tallman MS, Rowe JM & Goldstone AH. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109, 944-950, (2007). 30 Bhojwani D & Pui C-H. Relapsed childhood acute lymphoblastic leukaemia. The Lancet Oncology 14, e205-e217, (2013). 31 Curran E & Stock W. How I treat acute lymphoblastic leukemia in older adolescents and young adults. Blood 125, 3702-3710, (2015). 32 Gandemer V, Chevret S, Petit A, Vermylen C, Leblanc T, Michel G, Schmitt C, Lejars O, Schneider P, Demeocq F, Bader-Meunier B, Bernaudin F, Perel Y, Auclerc MF, Cayuela JM, Leverger G, Baruchel A & Group F. Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol. Haematologica 97, 1743-1750, (2012). 33 van Delft FW, Horsley S, Colman S, Anderson K, Bateman C, Kempski H, Zuna J, Eckert C, Saha V, Kearney L, Ford A & Greaves M. Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia. Blood 117, 6247-6254, (2011). 34 Kuster L, Grausenburger R, Fuka G, Kaindl U, Krapf G, Inthal A, Mann G, Kauer M, Rainer J, Kofler R, Hall A, Metzler M, Meyer LH, Meyer C, Harbott J, Marschalek R, Strehl S, Haas OA & Panzer-Grumayer R. ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling. Blood 117, 2658-2667, (2011). 35 Inaba H & Pui C-H. Glucocorticoid use in acute lymphoblastic leukaemia. The Lancet Oncology 11, 1096-1106, (2010). 36 Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA, Heatley SL, Holmfeldt L, Collins-Underwood JR, Ma J, Buetow KH, Pui CH, Baker SD, Brindle PK & Downing JR. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471, 235-239, (2011). 37 Brown JA & Ferrando A. Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: BIM Finally. Cancer Cell 34, 869-871, (2018). 38 Marke R, Havinga J, Cloos J, Demkes M, Poelmans G, Yuniati L, van Ingen Schenau D, Sonneveld E, Waanders E, Pieters R, Kuiper RP, Hoogerbrugge PM, Kaspers GJ, van Leeuwen FN & Scheijen B. Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia. Leukemia 30, 1599-1603, (2016). 39 Bauer AK, Faiola B, Abernethy DJ, Marchan R, Pluta LJ, Wong VA, Roberts K, Jaiswal AK, Gonzalez FJ, Butterworth BE, Borghoff S, Parkinson H, Everitt J & Recio L. Genetic susceptibility to benzene-induced toxicity: role of NADPH: quinone oxidoreductase-1. Cancer Research 63, 929-935, (2003). 40 Lindsey RH, Jr., Bender RP & Osheroff N. Effects of benzene metabolites on DNA cleavage mediated by human topoisomerase II alpha: 1,4-hydroquinone is a topoisomerase II poison. Chemical Research in Toxicology 18, 761-770, (2005). 41 Siew EL, Chan KM, Williams GT, Ross D & Inayat-Hussain SH. Protection of hydroquinone-induced apoptosis by downregulation of Fau is mediated by NQO1. Free Radical Biology and Medicine 53, 1616-1624, (2012). 42 Whysner J, Vijayaraj Reddy M, Ross PM, Mohan M & Lax EA. Genotoxicity of benzene and its metabolites. Mutation Research/Reviews in Mutation Research 566, 99-130, (2004). 43 Inayat-Hussain SH, Winski SL & Ross D. Differential involvement of caspases in hydroquinone-induced apoptosis in human leukemic hl-60 and jurkat cells. Toxicology and Applied Pharmacology 175, 95-103, (2001). 44 Inayat-Hussain SH & Ross D. Intrinsic pathway of hydroquinone induced apoptosis occurs via both caspase-dependent and caspase-independent mechanisms. Chemical Research in Toxicology 18, 420-427, (2005). 45 Wu PL, Lin SB, Huang CP & Chiou RY. Antioxidative and cytotoxic compounds extracted from the sap of Rhus succedanea. Journal of Natural Products 65, 1719-1721, (2002). 46 Huang CP, Fang WH, Lin LI, Chiou RY, Kan LS, Chi NH, Chen YR, Lin TY & Lin SB. Anticancer activity of botanical alkyl hydroquinones attributed to topoisomerase II poisoning. Toxicology and Applied Pharmacology 227, 331-338, (2008). 47 Lin TY, Huang CP, Au LC, Chang YW, Hu CY & Lin SB. A cysteine-reactive alkyl hydroquinone modifies topoisomerase IIalpha, enhances DNA breakage, and induces apoptosis in cancer cells. Chemical Research in Toxicology 25, 2340-2351, (2012). 48 高意雯. 分析天然植物對苯二酚衍生物HQ17(3)對帶有t(4;11)染色體轉位急性淋巴性白血病細胞株RS4;11的影響 碩士 thesis, 國立臺灣大學, (2011). 49 陳佳瑋. 分析植物對苯二酚衍生物HQ17(3)對急性淋巴性白血病細胞株的抑制作用 碩士 thesis, 國立臺灣大學, (2016). 50 張耀仁. 分析植物對苯二酚衍生物HQ17(3)對帶有費城染色體之急性淋巴性白血病細胞株SUP-B15的抑制作用 碩士 thesis, 國立臺灣大學, (2013). 51 周映辰. 分析植物對苯二酚衍生物HQ17(3)對費城染色體陽性之急性淋巴性白血病細胞株SUP-B15的毒殺機制 碩士 thesis, 國立臺灣大學, (2018). 52 Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, Gottlieb E, Green DR, Hengartner MO, Kepp O, Knight RA, Kumar S, Lipton SA, Lu X, Madeo F, Malorni W, Mehlen P, Nunez G, Peter ME, Piacentini M, Rubinsztein DC, Shi Y, Simon HU, Vandenabeele P, White E, Yuan J, Zhivotovsky B, Melino G & Kroemer G. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death and Differentiation 19, 107-120, (2012). 53 Elmore S. Apoptosis: a review of programmed cell death. Toxicologic Pathology 35, 495-516, (2007). 54 Zhang JH & Xu M. DNA fragmentation in apoptosis. Cell Research 10, 205-211, (2000). 55 Chaitanya GV, Steven AJ & Babu PP. PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal 8, 31, (2010). 56 Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, Garcia-Saez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jaattela M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, Lopez-Otin C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Munoz-Pinedo C, Nagata S, Nunez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G & Kroemer G. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation 25, 486-541, (2018). 57 Kalkavan H & Green DR. MOMP, cell suicide as a BCL-2 family business. Cell Death and Differentiation 25, 46-55, (2018). 58 Kroemer G & Martin SJ. Caspase-independent cell death. Nature Medicine 11, 725-730, (2005). 59 Tait SW & Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nature Reviews: Molecular Cell Biology 11, 621-632, (2010). 60 Tait SWG & Green DR. Caspase-independent cell death: leaving the set without the final cut. Oncogene 27, 6452, (2008). 61 Du C, Fang M, Li Y, Li L & Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33-42, (2000). 62 Hegde R, Srinivasula SM, Zhang Z, Wassell R, Mukattash R, Cilenti L, DuBois G, Lazebnik Y, Zervos AS, Fernandes-Alnemri T & Alnemri ES. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. Journal of Biological Chemistry 277, 432-438, (2002). 63 Lorenzo HK & Susin SA. Mitochondrial effectors in caspase-independent cell death. FEBS Letters 557, 14-20, (2004). 64 Miramar MD, Costantini P, Ravagnan L, Saraiva LM, Haouzi D, Brothers G, Penninger JM, Peleato ML, Kroemer G & Susin SA. NADH oxidase activity of mitochondrial apoptosis-inducing factor. Journal of Biological Chemistry 276, 16391-16398, (2001). 65 Sevrioukova IF. Apoptosis-inducing factor: structure, function, and redox regulation. Antioxid Redox Signal 14, 2545-2579, (2011). 66 Bano D & Prehn JHM. Apoptosis-Inducing Factor (AIF) in Physiology and Disease: The Tale of a Repented Natural Born Killer. EBioMedicine 30, 29-37, (2018). 67 Otera H, Ohsakaya S, Nagaura Z, Ishihara N & Mihara K. Export of mitochondrial AIF in response to proapoptotic stimuli depends on processing at the intermembrane space. EMBO Journal 24, 1375-1386, (2005). 68 Norberg E, Orrenius S & Zhivotovsky B. Mitochondrial regulation of cell death: processing of apoptosis-inducing factor (AIF). Biochemical and Biophysical Research Communications 396, 95-100, (2010). 69 Mizushima N & Komatsu M. Autophagy: renovation of cells and tissues. Cell 147, 728-741, (2011). 70 Kaushik S & Cuervo AM. The coming of age of chaperone-mediated autophagy. Nature Reviews: Molecular Cell Biology 19, 365-381, (2018). 71 Dikic I & Elazar Z. Mechanism and medical implications of mammalian autophagy. Nature Reviews: Molecular Cell Biology 19, 349-364, (2018). 72 Hansen M, Rubinsztein DC & Walker DW. Autophagy as a promoter of longevity: insights from model organisms. Nature Reviews: Molecular Cell Biology 19, 579-593, (2018). 73 Bialik S, Dasari SK & Kimchi A. Autophagy-dependent cell death - where, how and why a cell eats itself to death. Journal of Cell Science 131, (2018). 74 Fulda S & Kogel D. Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy. Oncogene 34, 5105-5113, (2015). 75 Fuchs Y & Steller H. Live to die another way: modes of programmed cell death and the signals emanating from dying cells. Nature Reviews: Molecular Cell Biology 16, 329-344, (2015). 76 Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H & Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nature Reviews: Molecular Cell Biology 15, 135-147, (2014). 77 Almanza A, Carlesso A, Chintha C, Creedican S, Doultsinos D, Leuzzi B, Luis A, McCarthy N, Montibeller L, More S, Papaioannou A, Puschel F, Sassano ML, Skoko J, Agostinis P, de Belleroche J, Eriksson LA, Fulda S, Gorman AM, Healy S, Kozlov A, Munoz-Pinedo C, Rehm M, Chevet E & Samali A. Endoplasmic reticulum stress signalling - from basic mechanisms to clinical applications. FEBS J 286, 241-278, (2019). 78 Flamment M, Hajduch E, Ferre P & Foufelle F. New insights into ER stress-induced insulin resistance. Trends in Endocrinology and Metabolism 23, 381-390, (2012). 79 Sano R & Reed JC. ER stress-induced cell death mechanisms. Biochimica et Biophysica Acta 1833, 3460-3470, (2013). 80 Harding HP, Zhang Y & Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 397, 271-274, (1999). 81 Rajesh K, Krishnamoorthy J, Kazimierczak U, Tenkerian C, Papadakis AI, Wang S, Huang S & Koromilas AE. Phosphorylation of the translation initiation factor eIF2alpha at serine 51 determines the cell fate decisions of Akt in response to oxidative stress. Cell Death & Disease 6, e1591, (2015). 82 Hollien J, Lin JH, Li H, Stevens N, Walter P & Weissman JS. Regulated Ire1-dependent decay of messenger RNAs in mammalian cells. Journal of Cell Biology 186, 323-331, (2009). 83 Bhat TA, Chaudhary AK, Kumar S, O'Malley J, Inigo JR, Kumar R, Yadav N & Chandra D. Endoplasmic reticulum-mediated unfolded protein response and mitochondrial apoptosis in cancer. Biochim Biophys Acta Rev Cancer 1867, 58-66, (2017). 84 Redza-Dutordoir M & Averill-Bates DA. Activation of apoptosis signalling pathways by reactive oxygen species. Biochimica et Biophysica Acta 1863, 2977-2992, (2016). 85 Dickinson BC & Chang CJ. Chemistry and biology of reactive oxygen species in signaling or stress responses. Nature Chemical Biology 7, 504-511, (2011). 86 Fleury C, Mignotte B & Vayssiere JL. Mitochondrial reactive oxygen species in cell death signaling. Biochimie 84, 131-141, (2002). 87 Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M & Telser J. Free radicals and antioxidants in normal physiological functions and human disease. International Journal of Biochemistry and Cell Biology 39, 44-84, (2007). 88 Glasauer A & Chandel NS. Ros. Current Biology 23, R100-102, (2013). 89 Ray PD, Huang BW & Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cellular Signalling 24, 981-990, (2012). 90 Vanden Berghe T, Vanlangenakker N, Parthoens E, Deckers W, Devos M, Festjens N, Guerin CJ, Brunk UT, Declercq W & Vandenabeele P. Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features. Cell Death and Differentiation 17, 922-930, (2010). 91 Boya P & Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene 27, 6434-6451, (2008). 92 Yu L, Wan F, Dutta S, Welsh S, Liu Z, Freundt E, Baehrecke EH & Lenardo M. Autophagic programmed cell death by selective catalase degradation. Proceedings of the National Academy of Sciences of the United States of America 103, 4952-4957, (2006). 93 Bachmann PS, Gorman R, Papa RA, Bardell JE, Ford J, Kees UR, Marshall GM & Lock RB. Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia. Cancer Research 67, 4482-4490, (2007). 94 Tsapis M, Lieb M, Manzo F, Shankaranarayanan P, Herbrecht R, Lutz P & Gronemeyer H. HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. International Journal of Biochemistry and Cell Biology 39, 1500-1509, (2007). 95 Hetz C & Papa FR. The Unfolded Protein Response and Cell Fate Control. Molecular Cell 69, 169-181, (2018). 96 Bahar E, Kim H & Yoon H. ER Stress-Mediated Signaling: Action Potential and Ca(2+) as Key Players. International Journal of Molecular Sciences 17, (2016). 97 Kerkhofs M, Bittremieux M, Morciano G, Giorgi C, Pinton P, Parys JB & Bultynck G. Emerging molecular mechanisms in chemotherapy: Ca(2+) signaling at the mitochondria-associated endoplasmic reticulum membranes. Cell Death & Disease 9, 334, (2018). 98 Kimura S, Noda T & Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 3, 452-460, (2007). 99 Redmann M, Benavides GA, Berryhill TF, Wani WY, Ouyang X, Johnson MS, Ravi S, Barnes S, Darley-Usmar VM & Zhang J. Inhibition of autophagy with bafilomycin and chloroquine decreases mitochondrial quality and bioenergetic function in primary neurons. Redox Biol 11, 73-81, (2017). 100 Harper JW, Ordureau A & Heo JM. Building and decoding ubiquitin chains for mitophagy. Nature Reviews: Molecular Cell Biology 19, 93-108, (2018). 101 Ortega AL, Mena S & Estrela JM. Glutathione in cancer cell death. Cancers 3, 1285-1310, (2011). 102 Guha P, Dey A, Sen R, Chatterjee M, Chattopadhyay S & Bandyopadhyay SK. Intracellular GSH depletion triggered mitochondrial Bax translocation to accomplish resveratrol-induced apoptosis in the U937 cell line. Journal of Pharmacology and Experimental Therapeutics 336, 206-214, (2011). 103 Zhivotovsky B & Orrenius S. Calcium and cell death mechanisms: a perspective from the cell death community. Cell Calcium 50, 211-221, (2011). 104 Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M, Criollo A, Morselli E, Zhu C, Harper F, Nannmark U, Samara C, Pinton P, Vicencio JM, Carnuccio R, Moll UM, Madeo F, Paterlini-Brechot P, Rizzuto R, Szabadkai G, Pierron G, Blomgren K, Tavernarakis N, Codogno P, Cecconi F & Kroemer G. Regulation of autophagy by cytoplasmic p53. Nature Cell Biology 10, 676-687, (2008). 105 Feng Z, Zhang H, Levine AJ & Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proceedings of the National Academy of Sciences of the United States of America 102, 8204, (2005). 106 Marino G, Niso-Santano M, Baehrecke EH & Kroemer G. Self-consumption: the interplay of autophagy and apoptosis. Nature Reviews: Molecular Cell Biology 15, 81-94, (2014). 107 Eliopoulos AG, Havaki S & Gorgoulis VG. DNA Damage Response and Autophagy: A Meaningful Partnership. Front Genet 7, 204, (2016). 108 Georgakopoulos ND, Wells G & Campanella M. The pharmacological regulation of cellular mitophagy. Nature Chemical Biology 13, 136-146, (2017). 109 Hoshino A, Mita Y, Okawa Y, Ariyoshi M, Iwai-Kanai E, Ueyama T, Ikeda K, Ogata T & Matoba S. Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart. Nat Commun 4, 2308, (2013). 110 Polak R, Bierings MB, van der Leije CS, Sanders MA, Roovers O, Marchante JRM, Boer JM, Cornelissen JJ, Pieters R, den Boer ML & Buitenhuis M. Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1-driven B-cell precursor acute lymphoblastic leukemia. Haematologica 104, 738-748, (2019). 111 Leclerc GM, Zheng S, Leclerc GJ, DeSalvo J, Swords RT & Barredo JC. The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2alpha and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia. Leukemia Research 50, 1-10, (2016). 112 Takahashi H, Inoue J, Sakaguchi K, Takagi M, Mizutani S & Inazawa J. Autophagy is required for cell survival under L-asparaginase-induced metabolic stress in acute lymphoblastic leukemia cells. Oncogene 36, 4267-4276, (2017). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73989 | - |
dc.description.abstract | 急性淋巴性白血病為兒童常見癌症,起因於淋巴系造血相關基因、致癌基因(Oncogene)、酪胺酸激酶(Tyrosine kinase)基因等變異或轉位導致細胞分化生長機制異常。雖然以現今治療策略可以幫助80~90% ALL兒童病患達到完全緩解,然而少部分兒童及高比例成人ALL病患會對治療藥物無反應或產生藥物抗性,或者病患本身攜有高風險基因變異,不一定有合適的標靶治療藥物因此造成預後不佳,這些情況都成為了目前ALL治療研究與開發的重點與方向。
天然小分子化合物10’(Z),13’(E),15’(E)heptadecatrienylhydroquinone (HQ17(3)) 萃取自台灣漆樹。在過去文獻中已知具有選擇性抑制癌細胞的能力,在多種實質腫瘤細胞具有良好毒殺效果,其中於Huh7細胞發現HQ17(3)會結合性修飾DNA拓樸異構酶導致DNA斷裂、半胱胺酸蛋白酶(caspase)活化及引起氧化壓力;正常人類周邊血單核球細胞(PBMCs)在HQ17(3)環境下生長情形不會受影響,且施打HQ17(3)不危害健康大鼠生理機能。我們過去研究發現HQ17(3)對ALL細胞株的毒殺效果更佳(IC50約1~3μM),且短時間內即有作用(24小時),HQ17(3)在T-ALL細胞株Jurkat造成caspase-dependent細胞死亡而在B-ALL細胞株RS4;11及SUP-B15則造成caspase-independent細胞死亡,顯示在不同基因背景或細胞種系之下HQ17(3)可能引導的促死亡訊號與機制不盡相同。 本論文研究以帶有ETV6-RUNX1 t(12;21) 基因轉位且對ALL治療一線用藥Dexamethasone具抗性之ALL細胞株Reh作為實驗細胞模型,我們發現HQ17(3)處理之下Reh出現死亡特徵: 內膜外翻、caspase活化/PARP切割、粒線體膜電位喪失及細胞毒殺。然而以pan-caspase inhibitor z-VAD與HQ17(3)共處理無法緩解細胞死亡說明HQ17(3)造成Reh caspase-independent 細胞死亡;我們在HQ17(3)處理5個小時觀察到錯誤蛋白摺疊反應相關蛋白表現提升,表示HQ17(3)誘發內質網壓力,為了解鈣離子由內質網釋出是否導致粒線體膜電位喪失與損傷促進ROS壓力累積引發細胞死亡,利用鈣離子螯合劑BAPTA-AM或抗氧化劑vitamin C, glutathione可以減輕HQ17(3)誘導粒線體膜電位下降及細胞死亡,顯示鈣離子失衡及氧化壓力為促成細胞死亡之重要因素。HQ17(3)也會引發細胞自噬,利用自噬抑制劑chloroquine及bafilomycin A1可以顯著挽救粒線體膜電位喪失及細胞死亡,顯示過度自噬機制的發生可能為HQ17(3)引起細胞死亡當中之重要的角色。此外,我們發現HQ17(3)處理5小時細胞內粒線體總量即發生下降情形,雖然鈣離子螯合劑、抗氧化劑與細胞自噬抑制劑皆可削弱HQ17(3)造成之細胞死亡,但粒線體總量下降情形並未緩解。而HQ17(3)如何引發Reh細胞內質網壓力、細胞自噬與粒線體總量下降機制之間關連仍待深入探討。 在preB-ALL細胞模型中,HQ17(3)常可同時誘發內質網壓力、氧化壓力及細胞自噬,達到快速抑殺白血病細胞的效果。除探討HQ17(3)引發Reh細胞內機制外,我們也測試HQ17(3)是否可以與ALL治療一線用藥合併使用之可行性,結果顯示以低於HQ17(3) IC50濃度處理可以增加細胞對Dexamethasone的感受性。本論文研究期望透過了解HQ17(3)誘發細胞死亡詳細訊息傳遞或機轉,在未來能對高風險ALL治療藥物與合併用藥策略的發展有所助益。 | zh_TW |
dc.description.abstract | Acute lymphoblastic leukemia (ALL) is the most common cancer among children. The pathogenesis of ALL involves chromosomal translocation and genetic alterations which disrupt genes that regulate hemopoiesis, activate oncogenes or tyrosine kinases, and characterized by abnormal proliferation and differentiation of lymphoid precursor cells. Despite improvements in treatment protocols resulting in complete remission of around 80%~90% of pediatric ALL patients, prognosis remains poor in ALL patients who are of high-risk cytogenetic changes (both in children and adults) or those who are resistant to therapy. New strategies should be explored to improve ALL treatment outcome.
The 10’(Z),13’(E),15’(E) -heptadecatrienylhydroquinone (HQ17(3)) is a small natural molecule extracted from the sup of Rhus succedanea. Previous studies reported that HQ17(3) was cytotoxic to various types of cancer cell lines while it exerted no effect on PBMCs and the rat model. In Huh7 cells, HQ17(3) was found to be a topoisomerase IIα poison that caused DNA breakage, induced caspase activation and oxidative stress. We previously found that ALL cell lines were more sensitive to HQ17(3) (IC50: 1~3μM)than other malignant cell lines reported before and that HQ17(3) induced caspase-dependent cell death in T-ALL Jurkat cells and caspase-independent cell death in B-ALL RS4;11 and SUP-B15 cells, suggesting that HQ17(3) exerts potent anticancer activity on various ALL cells through different molecular pathways. Here we investigated the cytotoxic effect of HQ17(3) on ALL cell line Reh, which harbors ETV6-RUNX1 t(12;21) chromosome translocation and is resistant to ALL first-line drug Dexamethasone. Externalization of phosphatidylserine, caspases activation, and PARP cleavage in accompany with mitochondrial membrane potential loss and cell demise were observed in Reh cells upon HQ17(3) treatment. HQ17(3) cotreatment with pan-caspase inhibitor z-VAD could not restore cell viability, indicating that HQ17(3) induced caspase-independent cell death in Reh cells. In addition, we found HQ17(3) induced ER stress as revealed by upregulation of the unfolded protein response associated protein. To investigate whether calcium outflow following ER stress and subsequent oxidant stress might account for further mitochondria damage and cell death , we found that cotreatment of cells with calcium chelator BAPTA-AM or ROS scavengers (vitamin C, glutathione) partially attenuated HQ17(3)-induced MMP loss and cell death, indicating that perturbation of intracellular calcium homeostasis and ROS stress participated in the pro-death signaling. Furthermore, autophagy might also implicate in HQ17(3)-induced cell death as cotreatment cells with lysosome-targeting inhibitor Chloroquine and bafilomycin A1 could alleviate MMP loss and cell death. We also found that mitochondrial mass declined upon HQ17(3) treatment for 5 hours but could not be restored after treatment with calcium chelator, ROS scavenger or autophagy inhibitor. How ER stress, mitochondrial mass loss and autophagy signaling are integrated into each other remained to be defined. In preB-ALL cell models, HQ17(3) presented rapid cytotoxicity via inducing ER stress, ROS and extensive autophagy simultaneously. To investigate the clinical potential of HQ17(3), we tested its ability to sensitize Reh cells to ALL chemotherapeutic Dexamethasone. Synergy was observed between HQ17(3) and Dexamethasone combined treatment, indicating that HQ17(3) may be a promising chemosensitizer. However, further experiments and studies are required to obtain more insights into the cytotoxic mechanism, providing new therapeutic strategies for high risk ALL. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T08:15:58Z (GMT). No. of bitstreams: 1 ntu-108-R06424017-1.pdf: 3019942 bytes, checksum: fb62a6a91e6543e5697db8cbde4007f9 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 致謝 I
摘要 II Abstract IV 縮寫表 VI 目錄 VIII 圖目錄 XII 表目錄 XIII 附錄目錄 XIV 第一章 緒論 1 1.1 急性淋巴性白血病(Acute lymphoblastic leukemia) 1 1.1.1 急性淋巴性白血病簡介 1 1.1.2 急性淋巴性白血病的致病因素與臨床特徵 1 1.1.3 急性淋巴性白血病的診斷與分型 2 1.1.4 急性淋巴性白血病的治療與評估 3 1.1.5 急性淋巴性白血病基因變異與致癌機制 5 1.1.6 急性淋巴性白血病治療困境 6 1.2 對苯二酚衍生物HQ17(3)簡介 8 1.2.1 對苯二酚(Hydroquinone)代謝與引發死亡型態 8 1.2.2 對苯二酚衍生物HQ17(3)的結構與細胞毒性 9 1.3 計畫性細胞死亡 (Programmed cell death,PCD) 11 1.3.1 Type Ⅰ PCD:細胞凋亡(Apoptosis) 11 1.3.2 Type Ⅱ PCD:細胞自噬依賴性死亡(Autophagy-dependent cell death) 14 1.3.3 Type Ⅲ PCD:細胞壞死(Necroptosis) 15 1.4 內質網壓力(Endoplasmic reticulum stress) 16 1.4.1 錯誤摺疊蛋白反應(Unfolded protein response) 16 1.4.2 ER stress 誘導細胞死亡途徑 18 1.5 活性氧化物質(Reactive oxygen species) 18 1.5.1 活性氧分子的生成 18 1.5.2 細胞內抗氧化機制 19 1.5.3 ROS與細胞氧化傷害 19 1.5.4 ROS與細胞死亡 20 1.6 HQ17(3)對ALL細胞抑殺作用前期研究結果 21 第二章 研究目的與實驗設計 22 2.1 研究目的 22 2.1.1 研究動機 22 2.1.2 研究目的 22 2.2 實驗設計 23 第三章 材料與方法 24 3.1 實驗材料 24 3.1.1 細胞株 24 3.1.2 對苯二酚衍生物HQ17(3) 24 3.1.3 試藥/試劑組、抗體、儀器、軟體分析工具清單 24 3.1.4 各式溶液及配方 24 3.2 實驗方法 26 3.2.1 細胞解凍、培養與計數 26 3.2.2 細胞存活率分析 26 3.2.3 粒線體膜電位分析 27 3.2.4 粒線體總量分析 27 3.2.5 細胞內活性氧化物質測定 28 3.2.6 粒線體內鈣離子偵測 28 3.2.7 免疫螢光染色 28 3.2.8 西方墨點法 29 3.2.9 三磷酸腺苷產量試驗 31 3.2.10 數據統計 31 第四章 實驗結果 32 4.1 HQ17(3)對Reh細胞抑制與毒殺作用 32 4.1.1 HQ17(3)抑制Reh細胞生長 32 4.1.2 HQ17(3)引發Reh細胞出現死亡特徵 32 4.1.3 HQ17(3)引發Reh細胞caspase-independent cell death 34 4.2 HQ17(3)引起Reh細胞死亡並非藉由壞死性凋亡路徑 34 4.3 膜間蛋白AIF核轉移非導致HQ17(3)引發Reh細胞死亡之原因 35 4.4 HQ17(3)引發Reh細胞死亡及粒線體膜電位喪失與ROS相關 35 4.4.1 HQ17(3)不會導致Reh細胞內ROS產出變化 35 4.4.2 抗氧化劑可以部份回復HQ17(3)引起Reh細胞死亡及粒線體膜電位喪失 36 4.5 HQ17(3)引起內質網壓力 36 4.6 HQ17(3)引起鈣離子失衡可能促成Reh細胞死亡 37 4.6.1 HQ17(3)不會引起粒線體內鈣離子增加 37 4.6.2 HQ17(3)引起鈣離子失衡部分促成粒線體膜電位喪失及細胞死亡 38 4.7 HQ17(3)促進Reh細胞自噬 38 4.7.1 HQ17(3)促使Reh細胞自噬 38 4.7.2 抑制細胞自噬可以挽救粒線體膜電位喪失及細胞死亡 39 4.8 HQ17(3)引起粒線體總量下降 39 4.8.1 HQ17(3)處理早期即引起粒線體總量下降 40 4.8.2 HQ17(3)引起鈣離子失衡與氧化壓力並非粒線體總量下降原因 40 4.8.3 抑制細胞自噬不能挽救HQ17(3)引起粒線體總量下降 41 4.9 HQ17(3)與ALL治療一線用藥Dexamethasone合併處理可增強對Reh細胞抑制作用 41 4.9.1 Reh細胞對化療用藥Dexamethasone具有抗性 41 4.9.2 HQ17(3)與Dexamethasone合併處理可以增強抑制Reh細胞生長效果 41 第五章 討論 43 5.1 總結 43 5.2 HQ17(3)引起細胞內氧化壓力 43 5.3 HQ17(3)引起內質網壓力及鈣離子失衡 44 5.4 HQ17(3)引發粒線體總量下降之因素 45 5.5 HQ17(3)所促進之細胞自噬與細胞死亡 47 5.6 HQ17(3)的標的與ALL藥物應用 48 參考文獻 50 圖 61 表 81 附錄 86 | |
dc.language.iso | zh-TW | |
dc.title | 植物對苯二酚衍生物HQ17(3)對急性淋巴性白血病細胞株Reh的毒殺機制 | zh_TW |
dc.title | The Cytotoxic Effects of the Botanical Alkyl Hydroquinone Derivative HQ17(3) on Acute Lymphoblastic Leukemia Cell Line Reh | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林亮音,吳瑞菁,歐大諒,周獻堂 | |
dc.subject.keyword | 急性淋巴性白血病,ETV6-RUNX1,HQ17(3),內質網壓力,粒線體損傷,細胞自噬,細胞死亡, | zh_TW |
dc.subject.keyword | acute lymphoblastic leukemia (ALL),ETV6-RUNX1,HQ17(3),ER stress,mitochondrial dysfunction,autophagy,cell death, | en |
dc.relation.page | 99 | |
dc.identifier.doi | 10.6342/NTU201903631 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-08-15 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
顯示於系所單位: | 醫學檢驗暨生物技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 2.95 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。